Literature DB >> 34387864

Cannabis use among cancer survivors in the United States: Analysis of a nationally representative sample.

Elizabeth K Do1,2, Albert J Ksinan1, Sunny Jung Kim1,2, Egidio G Del Fabbro2,3, Bernard F Fuemmeler1,2.   

Abstract

BACKGROUND: Research on cannabis use among those with a history of cancer is limited.
METHODS: Prevalence of past-year cannabis use among individuals with and without a cancer history and predictors of use within these 2 groups were determined using data from the Population Assessment of Tobacco and Health study, a nationally representative, longitudinal survey conducted in the United States (waves 1-4; 2013-2018). Discrete time survival analyses were used to estimate baseline (wave 1) predictors (physical health status, mental health status, pain, and demographic variables) on past-year engagement with cannabis within individuals who reported a cancer diagnosis at wave 1 (n = 1022) and individuals who reported never having cancer at any wave (n = 19,702).
RESULTS: At the most recent survey, 8% of cancer survivors reported past-year cannabis use, compared with 15% of those without a cancer history. Across 4 time points, an estimated 3.8% of cancer survivors engaged with cannabis, as compared to 6.5% of those without a cancer history. Across both groups, older age and having health insurance were associated with lower likelihood of engaging in cannabis use, whereas greater levels of pain were associated with higher likelihood of engaging in cannabis use. Among those without a cancer history, being female, White, and having better mental health status were associated with lower likelihood of engaging in cannabis use.
CONCLUSIONS: Although cannabis use prevalence is lower among cancer survivors, the reasons for use are not markedly different from those without a cancer history. Continued monitoring of use, reasons for use, and harms or benefits is warranted. LAY
SUMMARY: Results from this study, which uses data from the Population Assessment of Tobacco and Health Study, indicate that cannabis use is generally increasing across cancer survivors and those without a history of cancer. Cancer survivors are using cannabis at slightly lower rates than those without a history of cancer. Factors related to pain seem to be more prevalent in cancer populations relative to the general population, and could be contributing to cannabis use within cancer survivor populations.
© 2021 American Cancer Society.

Entities:  

Keywords:  Population Assessment of Tobacco and Health (PATH); cancer; cannabis

Mesh:

Year:  2021        PMID: 34387864      PMCID: PMC8600683          DOI: 10.1002/cncr.33794

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  36 in total

1.  Recent Trends in the Prevalence of Marijuana Use and Associated Disorders in the United States.

Authors:  Richard A Grucza; Arpana Agrawal; Melissa J Krauss; Patricia A Cavazos-Rehg; Laura J Bierut
Journal:  JAMA Psychiatry       Date:  2016-03       Impact factor: 21.596

2.  Prevalence and correlates of marijuana use in Canada, 2012.

Authors:  Michelle Rotermann; Kellie Langlois
Journal:  Health Rep       Date:  2015-04       Impact factor: 4.796

Review 3.  Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms: Systematic review and meta-analysis.

Authors:  Jesse D Kosiba; Stephen A Maisto; Joseph W Ditre
Journal:  Soc Sci Med       Date:  2019-06-08       Impact factor: 4.634

Review 4.  Medical Marijuana and Marijuana Legalization.

Authors:  Rosalie Liccardo Pacula; Rosanna Smart
Journal:  Annu Rev Clin Psychol       Date:  2017-05-08       Impact factor: 18.561

Review 5.  Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials.

Authors:  Mary E Lynch; Fiona Campbell
Journal:  Br J Clin Pharmacol       Date:  2011-11       Impact factor: 4.335

6.  Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study.

Authors:  Gabrielle Campbell; Wayne D Hall; Amy Peacock; Nicholas Lintzeris; Raimondo Bruno; Briony Larance; Suzanne Nielsen; Milton Cohen; Gary Chan; Richard P Mattick; Fiona Blyth; Marian Shanahan; Timothy Dobbins; Michael Farrell; Louisa Degenhardt
Journal:  Lancet Public Health       Date:  2018-07

7.  Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS).

Authors:  Mark A Ware; Tongtong Wang; Stan Shapiro; Jean-Paul Collet
Journal:  J Pain       Date:  2015-09-16       Impact factor: 5.820

8.  Characteristics of adults seeking medical marijuana certification.

Authors:  Mark A Ilgen; Kipling Bohnert; Felicia Kleinberg; Mary Jannausch; Amy S B Bohnert; Maureen Walton; Frederic C Blow
Journal:  Drug Alcohol Depend       Date:  2013-05-15       Impact factor: 4.492

9.  Medical marijuana use in head and neck squamous cell carcinoma patients treated with radiotherapy.

Authors:  David A Elliott; Nima Nabavizadeh; Jeanna L Romer; Yiyi Chen; John M Holland
Journal:  Support Care Cancer       Date:  2016-03-23       Impact factor: 3.603

10.  Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use.

Authors:  Steven A Pergam; Maresa C Woodfield; Christine M Lee; Guang-Shing Cheng; Kelsey K Baker; Sara R Marquis; Jesse R Fann
Journal:  Cancer       Date:  2017-09-25       Impact factor: 6.860

View more
  2 in total

Review 1.  Cannabis, Cannabinoids and Cannabis-Based Medicines in Cancer Care.

Authors:  Donald I Abrams
Journal:  Integr Cancer Ther       Date:  2022 Jan-Dec       Impact factor: 3.279

2.  Mental Health Symptoms during the COVID-19 Pandemic among Cancer Survivors Who Endorse Cannabis: Results from the COVID-19 Cannabis Health Study.

Authors:  Diane L Rodriguez; Denise C Vidot; Marlene Camacho-Rivera; Jessica Y Islam
Journal:  Curr Oncol       Date:  2022-03-19       Impact factor: 3.677

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.